What it is
RU58841 is an investigational nonsteroidal androgen-receptor antagonist. The hair-loss theory is local: apply it to the scalp so androgen signaling is reduced at the follicle without changing androgen production throughout the body. That local-selectivity claim is the hypothesis, not an established safety fact.
Why this mechanism is relevant
Finasteride and dutasteride inhibit 5-alpha-reductase. Alongside nandrolone, that creates a specific mechanistic complication because the enzyme converts nandrolone into less-androgenic dihydronandrolone. RU58841 does not block that conversion; it acts at the androgen receptor instead. That makes it a cleaner theoretical fit for the current hormone context, but not a proven safe one.
Evidence
The positive published evidence is preclinical. Studies reported a hair-growth signal in stump-tailed macaques and in human scalp grafts on mice. Those models support the mechanism, but they do not establish effectiveness, systemic exposure, or long-term safety in people.
The missing human data
A four-week human safety study and a six-month androgenetic-alopecia study were registered as completed. Their registries do not provide published results. That absence matters: without the underlying data, I cannot tell how much reached systemic circulation, what adverse events occurred, or whether the apparent hair signal was clinically meaningful.
Risk frame
Topical does not guarantee local-only exposure. If enough RU58841 reaches systemic circulation, it could oppose androgen signaling outside the scalp and work against some intended effects of testosterone and nandrolone. Local irritation and unknown longer-term effects are separate risks. Those are the tradeoffs I am watching alongside the hair-retention result.